[go: up one dir, main page]

TW201613579A - Pharmaceutical composition for oral administration - Google Patents

Pharmaceutical composition for oral administration

Info

Publication number
TW201613579A
TW201613579A TW104120176A TW104120176A TW201613579A TW 201613579 A TW201613579 A TW 201613579A TW 104120176 A TW104120176 A TW 104120176A TW 104120176 A TW104120176 A TW 104120176A TW 201613579 A TW201613579 A TW 201613579A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
oral administration
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TW104120176A
Other languages
English (en)
Inventor
Hiroyuki Kojima
Masakazu Miyazaki
Mare Nishiura
Takashi Nishizato
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of TW201613579A publication Critical patent/TW201613579A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW104120176A 2014-06-24 2015-06-23 Pharmaceutical composition for oral administration TW201613579A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014129374 2014-06-24

Publications (1)

Publication Number Publication Date
TW201613579A true TW201613579A (en) 2016-04-16

Family

ID=54938194

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104120176A TW201613579A (en) 2014-06-24 2015-06-23 Pharmaceutical composition for oral administration

Country Status (9)

Country Link
US (1) US9775832B2 (zh)
EP (1) EP3162368A4 (zh)
JP (1) JPWO2015199115A1 (zh)
CN (1) CN106456612A (zh)
HK (1) HK1232144A1 (zh)
MX (1) MX362193B (zh)
PH (1) PH12016502285A1 (zh)
TW (1) TW201613579A (zh)
WO (1) WO2015199115A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318259B1 (en) 2015-07-03 2023-01-11 Astellas Pharma Inc. Stable pharmaceutical composition for oral administration
MX2020001877A (es) * 2017-08-18 2020-09-14 Abbvie Inc Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948810B2 (ja) 1980-03-22 1984-11-29 山之内製薬株式会社 ニカルジピン持続性製剤用組成物
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
CZ20022047A3 (cs) 1999-12-23 2003-09-17 Pfizer Products Inc. Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva
EP1864976B1 (en) * 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
JP5517327B2 (ja) * 2008-12-16 2014-06-11 日医工株式会社 口腔内崩壊錠用組成物
JP6063379B2 (ja) * 2011-04-22 2017-01-18 アステラス製薬株式会社 固形医薬組成物
JP2013180961A (ja) * 2012-02-29 2013-09-12 Astellas Pharma Inc Ws727713含有固形製剤
JP2014051470A (ja) * 2012-09-07 2014-03-20 Astellas Pharma Inc スルホニルアミジン化合物の結晶
CA2883126A1 (en) 2012-09-07 2014-03-13 Astellas Pharma Inc. Method for producing sulfonyl amidine compound

Also Published As

Publication number Publication date
CN106456612A (zh) 2017-02-22
EP3162368A1 (en) 2017-05-03
US9775832B2 (en) 2017-10-03
MX362193B (es) 2019-01-08
EP3162368A4 (en) 2018-03-07
US20170143678A1 (en) 2017-05-25
HK1232144A1 (zh) 2018-01-05
PH12016502285A1 (en) 2017-02-13
MX2016017402A (es) 2017-05-01
JPWO2015199115A1 (ja) 2017-04-20
WO2015199115A1 (ja) 2015-12-30

Similar Documents

Publication Publication Date Title
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
MY199007A (en) Pharmaceutical compositions comprising meloxicam
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
EP4467600A3 (en) Pharmaceutical compositions comprising meloxicam
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PH12016500170A1 (en) Formulation of syk inhibitors
MX394588B (es) Composición farmacéutica.
CL2017001479A1 (es) Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
PH12017502252A1 (en) Stable pharmaceutical composition for oral administration
EA201692298A1 (ru) Производные карбоксамидов
MX2017013896A (es) Composicion farmaceutica para administracion oral.
PH12016502285A1 (en) Pharmaceutical composition for oral administration
MY175971A (en) Heterocyclic acetamide compound
PH12016502527B1 (en) Stabilized desmopressin
NZ731220A (en) Methods for treating kidney disorders
TH167761A (th) องค์ประกอบทางเภสัชกรรมสำหรับให้ทางปาก
UA113436U (xx) Лікарський засіб для лікування ішемічних уражень тканин
MY203481A (en) Pharmaceutical compositions comprising meloxicam
UA91650U (uk) Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул